Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 185-191

  Rosenthal, J ^a   Sender, L ^a   Secola, R ^a   Killen, R ^a   Millerick, M ^a   Murphy, L ^a   Cairo, M S ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Antithrombin III; BMT; VOD

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFANT; LIVER FAILURE; LIVER VENOOCCLUSIVE DISEASE; MALE; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTICOAGULANTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; HEMORRHAGE; HEPARIN; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INCIDENCE; INFANT; INFUSIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SAFETY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 0029737984     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bearman SI, Anderson GL, Mori M et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-1736.
2. Jones RJ, Lee KSK, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
3. McDonald GB, Sharma P, Matthews DE et al. Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
4. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
5. McDonald GB, Hinds M, Fisher L, Schoch HG. Liver toxicity following cytoreductive therapy for marrow transplantation: risk factors, incidence, and outcome. Hepatology 1991; 14: 162 (abstr.).
6. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
7. Meresse V, Hartmann O, Vassal G et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135-141.
8. Ozkaynak MF, Weinberg K, Kohn D et al. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome. Bone Marrow Transplant 1991; 7: 467-474.
9. Carreras E, Grañena A, Rozman C. Hepatic veno-occlusive disease after bone marrow transplant. Blood Rev 1993; 7: 43-51.
10. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
11. Bearman SI, Hinds MS, Wolford JL et al. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407-411.
12. Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 72: 2834-2840.
13. Cahn JY, Flesch M, Brion A et al. Prevention of veno-occlusive disease of the liver after bone marrow transplantation: heparin or no heparin? Blood 1992; 80: 2149-2150.
14. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-2462.
15. Baglin TP, Harper P, Marcus RE. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant 1990; 5: 439-441.
16. Woolf B. On estimating relation between blood group and disease. Ann Hum Genet 1955; 19: 251-253.
17. Shulman HM, McDonald GB, Matthews D et al. An analysis of hepatic venoocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79: 1178-1191.
18. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after bone marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
19. Gordon B, Haire W, Kessinger A et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1991; 8: 497-502.
20. Harper PL, Jarvis J et al. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990; 5: 39-42.
21. Faioni EM, Krachmalnicoff A, Bearman SI et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993; 81: 3458-3462.